Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Biological agents for inflammatory bowel diseases (IBD) targeting tumor necrosis factor
(TNF) have changed the way to treat IBD refractory to standard medications and allowed us …

Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or
haematological malignancies, particularly in patients treated with chemotherapeutic agents …

Renal anemia is a complication of chronic kidney disease. Guidelines for safe and effective
treatment in patients with renal anemia are needed. The Japanese Society for Dialysis …

The coming wave of patent expiries of first generation commercialized biotherapeutical
drugs has seen the global market open its doors to close copies of these products. These …

Background: Asia is the largest, most populous and most heterogeneous continent in the
world. The number of patients with end-stage renal disease is growing rapidly in Asia …

Post-marketing drug surveillance for adverse drug events (ADEs) has typically relied on
spontaneous reporting. Recently, regulatory agencies have turned their attention to more …

Biological oncology products are integral to cancer treatment, but their high costs pose
challenges to patients, families, providers, and insurers. The introduction of biosimilar …

Interchangeability, immunogenicity and biosimilars | Nature Biotechnology Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …

Abstract The World Health Organization (WHO) issued guidelines for the regulatory
evaluation of biosimilars in 2009 and has provided considerable effort toward helping …